TR mechanism determines the management pathway
The same severe TR grade can mean very different things. Primary structural TR, secondary ventricular functional TR, device lead-associated TR, and atrial functional TR follow different clinical pathways. Before applying intervention criteria, define the mechanism.
An echo report confirms severe TR. The next question is not only 'how severe?' — it is 'why is it happening?' Is the valve apparatus directly abnormal? Is RV dilation driving leaflet tethering? Is a device lead interfering with leaflet closure? Or is long-standing AF and RA enlargement dilating the annulus? Same severity grade — different pathway.
Key takeaway
TR management starts with mechanism. Primary structural TR, secondary ventricular functional TR, device lead-associated TR, and atrial functional TR should not be pushed through the same intervention algorithm.
Key points
- Primary structural TR is caused by direct pathology of the tricuspid valve apparatus — leaflets, chordae, papillary muscles, or annulus.
- Secondary ventricular functional TR is driven by RV dilation, RV dysfunction, pulmonary hypertension, or left-sided heart disease causing annular dilation and leaflet tethering.
- Atrial functional TR is driven mainly by AF, RA enlargement, and annular dilation — often with relatively preserved RV systolic function.
- Device lead-associated TR requires evaluation of the lead-leaflet interaction. Lead presence alone does not prove causality.
- The wrong mechanism leads to the wrong pathway.
- Mechanism guides the evaluation pathway, but final decisions still depend on symptoms, RV function, venous congestion, pulmonary pressure, end-organ effects, procedural risk, and valve-team assessment.
- The TR Intervention Navigator uses mechanism as the first branching point.
When to read this
Read this when an echo report shows significant or severe TR and you need to decide which evaluation pathway applies. It is especially useful when the mechanism is not clearly stated — or when the patient has AF, a pacemaker or ICD lead, RV enlargement, pulmonary hypertension, or left-sided valve disease.
Primary structural TR: the valve apparatus is the problem
In primary structural TR, the tricuspid valve apparatus itself is abnormal. The problem may involve the leaflets, chordae, papillary muscles, or annulus.
Common causes include leaflet prolapse, flail leaflet, myxomatous degeneration, endocarditis, rheumatic disease, radiation heart disease, carcinoid syndrome, and trauma.
On echo, the mechanism is often visible: prolapse, flail, perforation, leaflet destruction, thickening, or restricted motion. The management pathway is valve-centered, with attention to symptoms, RV function, right-sided remodeling, and systemic venous congestion.
Secondary ventricular functional TR: the RV is driving the regurgitation
In secondary ventricular functional TR, the leaflets are usually structurally normal or only mildly abnormal. The regurgitation occurs because RV dilation, RV dysfunction, pulmonary hypertension, or left-sided heart disease enlarges the tricuspid annulus and tethers the leaflets, causing malcoaptation.
This pathway requires evaluation of the underlying driver: pulmonary hypertension, left-sided valve disease, heart failure, chronic lung disease, or congenital disease. The initial focus is on treating what is producing the RV pressure or volume burden — not on the tricuspid valve itself.
Treating the underlying left-sided disease may improve TR — but this is not guaranteed. Once annular dilation or RV dysfunction is established, TR can persist or progress even after mitral or aortic disease is corrected.
Atrial functional TR: AF and RA remodeling are the main drivers
Atrial functional TR is increasingly recognized in older patients with long-standing AF. The dominant mechanism is RA enlargement and tricuspid annular dilation — with structurally normal leaflets and relatively preserved RV systolic function. This distinguishes it clearly from ventricular functional TR, where RV dilation and dysfunction are central.
Initial management focuses on volume optimization, rate or rhythm control, and heart failure management. In advanced symptomatic severe TR, valve-team assessment may be appropriate. In ACC/AHA 2020, surgical evaluation remains the guideline-centered pathway; transcatheter options such as T-TEER are evolving and should be presented separately from the core guideline pathway.
Device lead-associated TR: the lead may be the mechanism — but prove it
A pacemaker or ICD lead crossing the tricuspid valve can cause TR by impinging on a leaflet, restricting leaflet motion, perforating a leaflet, or preventing coaptation.
But lead presence alone does not prove lead-caused TR. The lead may coexist with functional TR from RV dysfunction, pulmonary hypertension, or annular dilation. Echo evaluation should assess the lead-leaflet relationship, leaflet motion, jet origin, RV function, and pulmonary pressure context.
This pathway requires joint device and valve expertise. Lead extraction, lead revision, leadless pacing, surgical repair, replacement, or transcatheter valve intervention may all be considered depending on the case — and neither team alone can fully characterize the risk-benefit landscape.
| Mechanism | Primary driver | Typical RV function | Management focus |
|---|---|---|---|
| Primary structural | Leaflet / apparatus pathology | May be preserved or volume overloaded | Valve-centered evaluation |
| Secondary ventricular functional | RV dilation, PH, left-sided disease | Often impaired or pressure/volume overloaded | Treat underlying cause; assess annulus/RV; consider concomitant repair when relevant |
| Atrial functional | AF, RA enlargement, annular dilation | Relatively preserved | Rhythm/rate, volume, HFpEF context; valve-team assessment if severe and symptomatic |
| Device lead-associated | Lead impingement, restriction, perforation, malcoaptation | Variable | Device and valve team evaluation |
How it fits into the TR Intervention Navigator
The TR Intervention Navigator uses mechanism as the first branch. The same severe TR grade enters different pathways depending on whether the mechanism is primary structural, secondary ventricular functional, atrial functional, or device lead-associated.
Mechanism does not make the final decision. It tells you which pathway to use. Final decisions still depend on symptoms, RV function, right-sided remodeling, venous congestion, pulmonary pressure, end-organ dysfunction, procedural risk, and local treatment options.
- Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25–e197.
- Zoghbi WA, et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation. J Am Soc Echocardiogr. 2017.
- Dreyfus J, et al. Functional Tricuspid Regurgitation: A Need to Redefine. J Am Coll Cardiol. 2020.
Apply this in practice
After confirming mechanism, use the TR Intervention Navigator to evaluate the appropriate pathway.
Open TR Intervention Navigator